At Health Advances, we’re passionate about healthcare. We don’t just work with the industry, we’re part of the industry. Our leaders sit on boards. We’ve started companies and worked in business, scientific, technical, medical, and investment environments. The result is an unsurpassed level of industry understanding and knowledge that informs every project.
Mark has been advising senior medtech executives for 30 years. He co-founded Health Advances in 1992 after gaining ten years of strategy consulting experience in the healthcare industry as a Partner at Bain & Company, an international management consulting firm.
At Health Advances, Mark works extensively with clients to evaluate the commercial potential and develop market launch strategies for new medical devices and diagnostics. He also offers expertise in mergers and acquisitions work for strategic and financial buyers, having now contributed to over $75 billion in client transactions. He serves on the Advisory Boards of Water Street Healthcare Partners and Radius Ventures. He served on the Board of Directors of MassMEDIC for six years. Mark is a strong advocate for the industry through his work with AdvaMed and MDMA as well as frequent speaking engagements and publications.
Mark graduated magna cum laude from Dartmouth College with a degree in engineering and was elected Phi Beta Kappa. He earned his MBA from the Stanford Graduate School of Business where he was honored as an Arjay Miller Scholar.
Paula co-founded Health Advances over 25 years ago, and continues to lead senior level client engagements focused on strategies to evaluate and optimize the value of developmental and marketed products and services, business units and companies in the healthcare arena.
She leads Health Advances’ Private Equity and Diligence Practice, the Global Orthopedics Practice and the firm’s Eye Care Sector Practice Specialty. She is deeply involved in leading Comparative Effectiveness and Pricing/Reimbursement/Market Access projects for clients, as well as developing overall growth strategies for companies and new products in development. She is also committed to applying Health Advances’ skills and expertise in the firm’s rapidly expanding HIT practice.
Paula works with clients of all sizes across the device, therapeutics, diagnostics, health IT, and services sectors, as well as with investors and non-profit organizations participating in these sectors. She brings strong quantitative skills to bear on projects, while applying her 32+ years of strategy, project management and client advisory skills to ensure insightful and actionable results. Paula has also played a leading role in designing and helping to build Health Advances’ Knowledge Management function and process. This includes the development of proprietary databases and analytic tools, as well as the codification of external and internal healthcare resources and knowledge, which enable the firm to provide the most insightful, data-driven and efficient insights on all of its projects.
Paula started her strategy consulting career at Bain & Company where she led engagements across a range of industries, including healthcare, with a particular focus on technology-driven businesses, manufacturing, and international ventures. Prior to business school, she served as a Tuberculosis (TB) Control worker with the US Peace Corps in South Korea, followed by work with Samsung Shipbuilding and the Atlantic Richfield Northern Light Project at Daewoo Shipbuilding Company, also in South Korea.
Paula graduated from Dartmouth College with honors in International Government. She received her MBA from Columbia University, where she earned Beta Gamma Sigma honors and was an International Fellow.
Andrew is a leader of Health Advances’ biopharma practice. He specializes in helping companies formulate development, commercialization, and lifecycle management strategies to grow the value of products and franchises.
Andrew has led over one hundred projects for global biopharmaceutical companies, start-up biotechs, private equity investors, healthcare service businesses, and nonprofits. His therapeutic area experience spans oncology, autoimmune diseases, pulmonology, CNS diseases, gastroenterology, critical care, and many orphan conditions. He is also an expert in drug distribution for specialty products and has worked with drug manufacturers and pharmacies on their distribution channel strategies. In his nonprofit work, Andrew has assisted the Michael J. Fox Foundation and the National Parkinson Foundation with major strategic planning projects.
Andrew joined Health Advances in 2005 with a strong background in corporate strategy, finance, and strategic planning. Prior to Health Advances, Andrew worked with Michael Porter of the Harvard Business School on business strategy and healthcare policy, and with Monitor Group, where he split his time between the Pharmaceutical and Corporate Finance practices. He also worked in Genentech’s internal strategic planning group. Andrew earned an AB in economics, summa cum laude, and a minor in operations research from Princeton University, and an MBA with distinction from the Harvard Business School.
Sheela is a leader in Health Advances’ biopharma practice, helping companies maximize the value of their assets and build winning market positions.
Experienced in multiple therapeutic areas, she has particular expertise in metabolic and autoimmune diseases. Sheela brings a cross-sector lens to her biopharma clients, providing strategic advice on integrated solutions and convergent products.
Sheela joined Health Advances in 2005 with a background in corporate strategy and health care provider operations. Prior to Health Advances, Sheela worked at The Advisory Board where she managed client relationships and led research teams in areas related to hospital care delivery and new payment models. She also worked at Novartis Pharmaceuticals in the Cardiovascular Business Franchise.
Sheela earned a BA in human biology with university distinction and Phi Beta Kappa from Stanford University, and an MBA from the Harvard Business School.
Gary joined Health Advances in 2005 and leads the firm’s Personalized Medicine Practice.
A noted writer and workshop leader in the field of companion diagnostics and personalized medicine, his work focuses on commercialization strategy, indication prioritization, pricing and reimbursement strategy, system economics, and business development opportunities for both diagnostic and therapeutic clients.
Prior to joining Health Advances, Gary was a researcher at Brookhaven National Lab evaluating a proprietary line of synthetic growth factors. Gary also worked in the Cell & Tissue Technologies group at Becton Dickinson, the Exploratory Cancer Research group at OSI Pharmaceuticals, and most recently the Corporate Strategy group at Millennium Pharmaceuticals. Gary received his BSE degree in Biomedical Engineering from Duke University and his MS degree in Biomedical Engineering from Stony Brook University.
Susan co-leads the Medtech Practice Group at Health Advances, where she has worked on over 200 project engagements, with a wide variety of clients ranging from small start-ups to some of the largest public companies in the industry.
Susan’s work with these companies has helped to optimize the value of products and technologies through extensive market evaluations, due diligence of M&A opportunities, and the development of strategies for sales and marketing efforts. She has extensive experience in the device sector, including women’s health, urology and critical care. Susan has published articles in a number of industry journals including a Medtech Insight article focusing on the value proposition for medtech products and is a previous MassMEDIC board member.
Prior to joining Health Advances in 2000, Susan worked at Interneuron Pharmaceuticals, Inc. in the areas of business development, marketing, and product management. Susan’s high technology experience also includes Molten Metal Technology, Inc. Susan earned her BA in General Science with a minor in Business and Managerial Economics from Brandeis University.
Vivek leads Health Advances’ San Francisco office and is focused on building Health Advances’ expertise in translational medicine through his work across therapeutics, diagnostics, and life science tools.
This broad exposure allows Vivek to leverage his scientific background to help companies across the spectrum of discovery, development, and commercialization of novel technologies. A core component of Vivek’s work is in opportunity identification, either for new platform technologies or for companies seeking to expand into new markets. Experienced in multiple therapeutic areas, he has particular expertise in immunology, oncology, ophthalmology, and orphan disease.
Prior to his work at Health Advances, Vivek earned his PhD in Molecular Cell Biology at Washington University in Saint Louis, studying G-protein regulation. While at WashU, Vivek founded the BioEntrepreneurship Core (BEC), a program designed to introduce life science students to the drug development process. BEC was a awarded a Kauffman Grant and has gone on to train many like-minded students.
Vivek received a BA in Biochemistry/Molecular Biology and an MA in Biotechnology from Boston University.
Donna joined Health Advances in 2005 and leads the firm’s Diagnostics and Life Science Tools Practice, a global practice which combines her consulting and scientific experience to provide results-oriented commercialization strategies for her clients.
Her work includes application and R&D prioritization, launch strategy, corporate strategy and portfolio optimization, deal diligence, international and domestic market analysis using both qualitative and quantitative approaches, and pricing and reimbursement strategies. Her clients offer products and services in personalized medicine, point-of-care, mainstream clinical diagnostic, and life science tools and range from small diagnostics and tools start-ups to the largest public companies and non-profit institutions in the industry.
Prior to joining Health Advances, Donna worked as a scientist at One Cell Systems and Iquum developing diagnostics for oncology and infectious diseases. She received her Bachelor’s degree in Biology from the University of Illinois at Urbana-Champaign and her PhD in Immunology from the Sackler School of Biomedical Sciences at Tufts University.
Wyatt brings 20 years of life sciences experience to Health Advances, and joined the firm after a successful career leading teams in strategy development, product and portfolio management, and new product commercialization in the biopharma and medtech industries.
Wyatt helps lead Health Advances’ Biopharma practice and focuses on commercial growth and business development strategies for therapeutics and their convergence with med tech in our Digital Health and Drug Delivery work.
Immediately prior to joining Health Advances, Wyatt worked at the Boston Consulting Group (BCG) where he advised global biopharma and medtech clients and led teams in growth and product launch strategies, M&A integration, and organizational optimization. He previously worked at Biogen as the Head of New Product Commercialization, developing clinical and commercial strategies for pipeline programs in neurology, immunology and oncology, while supporting corporate and business development activities. Earlier, at Boston Scientific Corporation, Wyatt created and led a new function to achieve market access with US commercial health plans, supporting launches across their portfolio and business units.
Wyatt earned his BS degree in Economics & Policy Analysis and an MPA degree, including a certificate from the Sloan Graduate Program in Health Services Management, at Cornell University. He serves as an Adjunct Faculty member / Executive in Residence of the Executive Master in Health Administration Program at Cornell. He is also on the Faculty of the Fundamentals in Business Development course offered annually during the BIO International Conference.
Andrew joined Health Advances in 2009. He co-leads the firm’s Digital Health and Health IT Practice.
Andrew applies his deep expertise in commercial strategy and product development strategy in healthcare to a wide range of digital technology areas, including digital therapeutics, connected devices and diagnostics, wearables, remote patient monitoring, medication adherence, advanced analytics, clinical decision support, precision medicine software, real world evidence, and data monetization.
Andrew works closely with clients in digital health, tech, and the life sciences, as well as with investors in these areas, to help maximize the value of these exciting and rapidly evolving technologies.
Additionally, Andrew also works regularly with clients in private equity and medtech on a range of non-digital strategy questions, leveraging his extensive experience across many categories of medical equipment, consumables, and services in acute, ambulatory, and home settings.
Serving as a Strategic Advisor to the Digital Therapeutics Alliance, Andrew works closely with leading companies in digital therapeutics and biopharma to help pave the way for acceptance and adoption of digital therapeutics.
Prior to Health Advances, Andrew was a Consultant at Bain & Company and Axia Limited, where he focused on supply chain strategy, operational efficiency, cost reduction, and merger integration. He also worked at Novartis in the global cardiovascular-metabolic franchise.
Andrew earned his BA degree in Political Science, magna cum laude and Phi Beta Kappa, from Yale University and an MBA from Harvard Business School, where he was honored as a Baker Scholar.
Julia has accumulated over 20 years of experience in global pricing, market access, health economics, health policy and health services research in both the biopharma industry and academic research.
A mathematical modeler by training, she leads Health Advances’ Market Access and Policy Strategy Practice, serving biopharma, medtech, diagnostics, and digital health clients.
Immediately prior to joining Health Advances, Julia worked at Biogen as Senior Director, Global Medical Outcomes Strategy where she provided strategic leadership and technical health outcomes expertise to ensure that medical product strategies and tactics anticipated the evolving demands of the global payer landscape. At Biogen she was also Director, Global Market Access where she built and managed a team of Health Economics and Outcomes Researchers (HEOR) responsible for payer value evidence development for the Company’s late stage development products. In that capacity Julia led the global reimbursement and market access launches for TECFIDERA and FAMPYRA for Multiple Sclerosis. Julia has also held related positions at Amylin Pharmaceuticals, Hoffmann-La Roche, and the RAND Corporation where she supported payer and ‘Real World Evidence’ development for Phase II/III products in Diabetes, Obesity, HIV/AIDs and Hepatitis.
Julia holds a Doctorate in Health Policy and Decision Analysis from Harvard University, a Masters in International Economics from Johns Hopkins University, and a BA from the University of Pennsylvania. She has held Adjunct Faculty positions at UCSD Division of Global Public Health and at the RAND Corporation and has published many articles on health technology assessment in journals such as Nature, Journal of Vascular Surgery, Health Services Research, Diabetes Medicine, and Plos Medicine. Julia is an Independent Director at Atlas5D.
Tracy works with a wide variety of medical device clients ranging from small start-ups to some of the largest public companies in the industry.
She partners with clients to develop growth strategies for medtech products across sites of care including hospital and physician office, and has extensive experience in many therapeutic areas including neurology, ophthalmology, and cardiology.
Prior to joining Health Advances in 2006, Tracy worked at the Equinox Group where she advised pharmaceutical companies on the commercial outlook of developmental agents to support licensing and product development decisions. She also worked at Johnson & Johnson Health Care Systems on internal consulting projects for various Johnson & Johnson operating companies, including both medical device and pharmaceutical companies.
Tracy earned a BS in statistics from Lehigh University, and an MBA from the University of Michigan Ross School of Business with an emphasis in Corporate Strategy.
Claudia brings over 20 years of experience in the healthcare industry – both as a consultant and as a line manager – to her role leading Health Advances’ European Practice. Based in Zug, Switzerland, Claudia oversees all of Health Advances research in European markets and is responsible for many European client relationships.
Claudia most recently led the Medical Affairs and Technology functions at Anteis SA, a biotechnology company with biopolymers for aesthetic, orthopedic, and ophthalmic applications. Previously, Claudia focused largely on international strategic planning and marketing with senior executive positions at Johnson&Johnson and Stryker with responsibilities for the EMEA, Africa, and Asia Pacific.
Claudia started her career as a management consultant for Arthur D. Little AG and has run Graeve Consulting Sarl as an independent consultant across the biopharma and medtech sectors.
Claudia earned her Master of Science degree in Chemistry from the University of Münster (Westfälische Wilhelmsuniversität), in Münster, Germany, graduating in the Top 5% of her class. She then received her PhD in Organic Chemistry from the same university, earning magna cum laude honors. She later earned her MBA at the Bocconi School of Management in Milan.
A true pan-European executive, Claudia has lived and worked in the UK, Switzerland, Italy, and Germany. She speaks German, English, French, and Italian fluently and has proficiency in Spanish and Portuguese.
Kate joined the Health Advances team in 2009 and works across the Therapeutics and Diagnostics/Life Science Tools practices.
She has expertise in supporting the development and launch of novel therapeutics and diagnostic technologies through voice of the customer analysis, competitive landscape assessment, and scenario-based forecasting.
Prior to joining Health Advances, Kate received a PhD in Immunology from Harvard University, where her research focused on developing immunoassays to detect and characterize rare and low-affinity autoantibodies specific for native myelin antigens in multiple sclerosis. She received a Bachelors of Science in Biology from Case Western Reserve University.
Dean is a leader in the Health Advances’ biopharma practice. He focuses on Commercialization and Launch Excellence in the Emerging Biopharma and Medtech industries. He has expertise in developing Go-to-Market strategies along with operational plans to support launch decision making frameworks across a variety of large and orphan disease segments in the US and EU.
Prior to joining Health Advances in 2017, Dean was a principal at QuintilesIMS Consulting where he focused on commercialization of assets. He has extensive experience in data sources/analytics, primary and secondary market research to support forecast as well as commercial strategy informed by P&Ls to drive asset valuations for acquisition and licensing decisions. Prior to this work, Dean was an independent commercial consultant working with start-up companies to optimize their launch planning and execution in a variety of therapeutic areas. He has extensive experience in Anti-Infectives, CNS, Gastroenterology, Immunology, Metabolic, Ophthalmology and Oncology.
During his twenty-year career on the client side of the business at GlaxoSmithKline and Sepracor/Sunovion, Dean held senior positions in sales and sales management, product management, market research and business development. Over the course of his career, Dean has directed the launch of over 10 NCEs, indications and line extensions in numerous therapeutic areas. His teams were the recipients of multiple CEO awards based on innovative launch programs and sales performance.
Dean received a BS in Pharmacy from the Massachusetts College of Pharmacy and is a Registered Pharmacist in the State of New Jersey. He also received an MBA from Lubin School of Business at Pace University in New York City.
Greg co-leads Health Advances’ Health IT and Digital Health practice, building upon fifteen years of experience in strategy, management consulting, marketing, operations, and technology leadership.
A computer engineer and manager by training, Greg’s career has included technical software development and product management; strategic growth consulting to the Fortune 500; product management; B2B marketing and communications; and senior operations leadership.
Prior to Health Advances, Greg held multiple senior executive roles at Arcadia Healthcare Solutions, a leader in population health analytics and EHR data integrations serving health systems, accountable care organizations, and health plans nationwide. Greg founded and ran a Strategic Marketing team after an initial round of growth equity and drove company-wide business planning, performance improvement and measurement programs as the Strategic Operations leader. Earlier in his tenure, he was the product director for the core analytics platform and a principal consultant in Arcadia’s legacy consulting business. While at Arcadia, Greg also served as a subject matter expert to the Office of the National Coordinator for HIT on health information exchange (HIE) under the federal HIE, Regional Extension Center, and Beacon Community grant programs.
Greg began his career as a case team leader and technical project manager at Monitor Group (now part of Deloitte), serving clients in the biopharma, high tech, and government sectors.
Greg holds a Masters of Engineering Management degree from the Thayer School of Engineering at Dartmouth College, a collaborative program with the Tuck School of Business. He holds a BE and BA in Engineering and Computer Science, also from Dartmouth College.
At Health Advances, Carrie works towards the advancement of novel therapeutics, drawing from experience across commercialization and development strategies and benchmarking, new product planning, and market evaluation.
Her clients have ranged from small start-ups and university technology transfer offices to the largest biopharmaceutical companies and private equity firms. With experience across multiple therapeutic areas, she is particularly interested in specialty markets including orphan, autoimmune, and respiratory diseases. Carrie also supports in vitro diagnostics clients with the development of strategies for core lab, point-of-care, and emerging new technologies.
Prior to joining Health Advances in 2007, Carrie received her MS degree in organic chemistry from Massachusetts Institute of Technology, and she worked for several years as a medicinal chemist at Merck & Co., Inc. in Rahway, New Jersey where she developed her interests in drug discovery and development.
Carrie received a BA in chemistry from Williams College.
Balazs has over 15 years of healthcare experience in corporate development, strategy, finance and operational positions. He joined Health Advances after a successful career with biopharma companies ranging from industry leading biotechnology firms to small start-up operations.
Balazs brings to Health Advances a combination of big picture strategic approach and hands-on implementation experience. Throughout his career he was responsible for solving strategic problems, executing high value business development transactions and building high-performing organizations.
Immediately prior to joining Health Advances, Balazs was part of the management team of Lyndra, a biotechnology start-up developing an ultra-long acting drug delivery technology. As Vice President of Operations, Balazs was responsible for all aspects of business operations, helping build the company to a 25-strong operation, secure financing and jump-start critical manufacturing R&D projects.
Prior to that, Balazs served as Senior Director, Corporate Development at Ironwood Pharmaceuticals. He formulated the company’s emerging market strategy and executed a complex joint venture transaction with Astra Zeneca for the development and commercialization of Ironwood’s flagship product, LINZESS® in China, Hong Kong and Macau. He was also responsible for two co-promotion agreements that leveraged and strengthened Ironwood’s sales capabilities in the US market.
Earlier in his career Balazs spent six years at Biogen where he helped build the company’s Patient Support Services organization. Leading a diverse cross-functional team and managing a multi-million dollar budget, Balazs significantly improved key operational metrics such as patient conversion and therapy adherence rates. He also negotiated several of Biogen’s key product distribution and service agreements.
Balazs holds a Master of Science in Economics from Corvinus University in Budapest, Hungary as well as an MBA in Finance from the Wharton of School of Business at the University of Pennsylvania. He graduated with honors from both institutions.
Darcy has 20 years of strategic healthcare consulting experience, having advised medical device, biopharma, and diagnostic clients in the areas of new product development, market access and commercialization strategies.
At Health Advances, Darcy partners with clients to create and capture the full value of their medical devices, supplies, and services in acute, ambulatory, and home settings globally. With expertise across multiple therapeutic areas, she has particular interest in wound care, vascular access, surgical devices and supplies, and other hospital-based equipment.
Prior to Health Advances, Darcy was a Principal in GfK’s Market Access Practice, co-leading the Medical Device Center of Excellence. In this role, Darcy led projects related to coding, coverage, reimbursement, and pricing strategies as well as the development of tactical materials to convey value for medical devices and prophylactic vaccines. She has extensive experience in primary and secondary market research to support evidence planning, value story development, pricing and forecasting. She has also held consulting roles with increasing responsibility at Abt Associates, Arthur D. Little and Decision Resources Group (DRG) Consulting. Darcy earned a BA in psychology from Bates College.
Ruggero brings 15 years of life science experience to Health Advances’ biopharma practice. He focuses on corporate strategy, business development, growth strategy, portfolio rationalization, and marketing strategy.
Ruggero has substantial expertise in specialty pharmaceuticals, with an emphasis on oncology and rare disease, and has direct work experience in the United States as well as major European markets.
Prior to joining Health Advances, Ruggero worked at Takeda Oncology, where he focused on R&D strategy and business development. In this role, he was responsible for the identification and execution of strategic partnerships in the immuno-oncology space. Previously, Ruggero led corporate strategy initiatives at Vertex Pharmaceuticals, including corporate-level portfolio prioritization and geographic expansion strategy.
Before his corporate career, Ruggero was a management consultant at Monitor Group, where he led high-profile engagements with life science companies, with a focus on competitive and marketing strategy. During his ten-year tenure at Monitor, he developed significant expertise in advising executive teams on complex business decisions through the development of customized strategy frameworks and the application of sophisticated market research and data analytics methodologies.
Recently, he served as Senior Lecturer at the MIT Sloan School of Management. As a member of the faculty for the school’s Global Entrepreneurship Lab, Ruggero advised student-led teams working on consulting engagements with entrepreneurial technology ventures in emerging markets.
Ruggero holds an MBA from the Kellogg School of Management at Northwestern University. He graduated magna cum laude from Bocconi University with a degree in Business Administration.
Kristen Garner Amanti joined the Health Advances team in 2010 and is a leader in the Reproductive and Genomic Health practice and Personalized Medicine practice.
She has deep experience in commercialization strategy, business development opportunity assessment, deal diligence, international and domestic market assessment, corporate strategy, and is a seasoned workshop facilitator. She has content expertise in companion diagnostics, reproductive and prenatal health, genomic health, cancer screening, tumor genetics and oncology.
Prior to joining Health Advances, Kristen received her PhD in Cancer Pharmacology from Dartmouth College where her research focused on the development of novel targeted cancer therapeutics. She received her Masters degree in Cell and Molecular Biology and Bachelors degree in Biology from the University of Vermont.
Peter has over 30 years of healthcare experience including corporate executive, principal investor and strategy consulting positions across diagnostics, life science research products, medical devices and biopharmaceuticals.
With an integrated view of technology commercialization, medical markets and corporate capability, Peter applies deep experience in advising clients on strategic decisions. He primarily focuses on Health Advances’ Diagnostics practice including core, specialty and point of care diagnostics.
From 2004 to 2018, Peter held executive leadership positions at Becton Dickinson, GE Healthcare and Ortho Clinical Diagnostics. In these roles he advised C-suite leadership and Boards of Directors, and led transformational licensing, partnership and M&A transactions. Notable transactions include the Ortho partnership with Quotient Biomedical, acquisition of Hyclone by General Electric, acquisition of Handylab at Becton Dickinson, and the point of care strategy and acquisition of assets for BD’s Veritor rapid diagnostics platform. Previously, he held positions as a Partner with Radius Ventures, as a consultant with The Wilkerson Group and Bain, and business development, marketing and sales positions with Schering-Plough, Genentech and Roche Laboratories, respectively.
Peter holds a Master of Science in Industrial Administration from the Tepper School at Carnegie Mellon University, and undergraduate degrees in Genetics and History from the University of California at Berkeley.
Kristine has over 15 years of Life Science industry experience that spans diagnostics, medical devices, and therapeutics. She has held positions in market planning, business analytics, marketing, and business development.
Most recently, Kristine spent four years at a small cap oncology molecular diagnostic company where she led marketing and planning. During that time, she helped to take the company public, led the portfolio management and corporate planning efforts, and developed the commercial plan for their launch. She led the team that was responsible for the full range of commercial activities including: product development requirements, pricing strategy, market access strategy, salesforce sizing and customer service.
In addition to her oncology experience, Kristine has worked in metabolics, with positions at Genentech and Abbott, and in maternal health (early stage molecular diagnostic company). During her career she has been on five product launch teams with responsibilities for launch planning and KPI tracking.
Prior to her Life Science career, Kristine spent 15 years in commercial positions in high tech.
Kristine has a PhD from the University of Chicago and has completed the Executive Program in Strategy and Organization from the Stanford Graduate School of Business. She is also an active member of Women in Bio.
Gary leads Health Advances’ Hong Kong office and is focused on growing the firm’s practice in the Asia Pacific with pharma, biotech, medtech, and private equity firms.
Gary brings over three decades of healthcare experience in general management (Aventis, Chiron, and Biosite) and mergers and acquisitions (Alere and Becton Dickinson) in the Asia Pacific region. He has expert knowledge in the fields of oncology and cardiovascular medicine in pharma, and point of care expertise in diagnostics. During his fourteen years at Novartis, he managed the global launch of one of the leading medicines in the oncology portfolio.
While at BD, Gary identified over fifty acquisition, licensing, and partnership targets in China, Japan, Southeast Asia, and India and led the integration of Carefusion in the Greater Asia region.
Immediately prior to joining Health Advances, Gary was a Partner/Managing Director at Stout Bluepeak Asia where he worked in portfolio planning, mergers & acquisitions, and capital raising for both regional multinational firms start-up firms in Asia.
He has lived and worked professionally in Japan, Hong Kong, Singapore, and Switzerland.
Gary received his BA with honors in Psychology and Biology from Brown University and his MS in Health Policy and Management from Harvard University.
Holger joined Health Advances in 2019. He is part of Health Advances’ biopharma practice.
Holger applies his deep expertise in commercializing scientific innovations in product development strategy, product positioning, and field force optimization across a wide range of technologies, including digital-, cell- and gene therapies. He is equally versed in life-cycle management and end-of-exclusivity transitions.
Immediately prior to joining Health Advances, Holger held Chief Commercial Officer positions at Biognosys AG, a leading mass spectrometry CRO with focus on proteome discoveries and Cell Medica, a cell therapy company, where Holger was responsible to launch one of the first cell therapy therapeutics into European markets. Holger also held the Chief Operating Officer position at Spiden an early stage medical device company using state-of-the-art detection technologies for vital medical indicator tracking. He previously worked in several senior commercial- and business development roles at Novartis Pharma, both at the global- and local affiliate level, while supporting development-stage and in-market projects across a wide area of therapeutic areas. Earlier, at Bain & Company, Holger consulted for leading pharmaceutical and Private Equity clients primarily on Due Diligences, M&A transitions, and post-merger integrations.
Holger earned his MS degree in Chemistry from the Leibniz University and his PhD from the Swiss Federal Institute of Technology. He earned the CFA designation from the CFA Institute.
Kristen joined Health Advances in 2011 overseeing all finance responsibilities serving as Chief Financial Officer for 7 years.
Kristen came to Health Advances, after earning her CPA with Deloitte and with strong prior controllership experience at both large and small private contractors in the Boston area.
Now, as Health Advances Managing Director and Chief Operating Officer, Kristen brings over 20 years in managerial, operational and financial management. She oversees and directs the administrative functions and infrastructure necessary to deliver the highest quality product to our clients.
Kristen earned her BS in Accounting from Merrimack College.